Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.48 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.43 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP4 | P49662 | 1/20 | 0.39 |
| ▸ | CASP5 | P51878 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 4/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11957992 | 0.94 | CNR1 (0.53) | CNR1MDM2OPRL1CACNA1GKDM4E | |
| SCHEMBL11957767 | 0.90 | MEN1 (0.46) | CNR1MDM2KDM4EALDH1A1LMNA | |
| SCHEMBL11957741 | 0.88 | CNR1 (0.54) | CNR1MDM2DRD4 | |
| SCHEMBL11958325 | 0.87 | CNR1 (0.62) | CNR1MDM2KDM4EALDH1A1DRD4 | |
| SCHEMBL11957716 | 0.87 | CNR1 (0.62) | CNR1MDM2KDM4EALDH1A1DRD4 | |
| SCHEMBL14787416 | 0.85 | CNR1 (0.49) | CNR1MDM2CACNA1GDRD4 | |
| SCHEMBL11958322 | 0.85 | LSS (0.48) | CNR1MDM2KDM4EDRD4CASP1 | |
| SCHEMBL11980141 | 0.85 | CNR1 (0.49) | CNR1MDM2KDM4EALDH1A1DRD4 | |
| SCHEMBL11957773 | 0.85 | CNR1 (0.49) | CNR1MDM2CACNA1GDRD4 | |
| SCHEMBL11957742 | 0.85 | CNR1 (0.49) | CNR1MDM2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236805-B2 | Substituted piperazines as CB1 antagonists | INTERVET INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236805-B2 | Substituted piperazines as CB1 antagonists | INTERVET INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-7700597-B2 | Substituted piperazines as CB1 antagonists | SCHERING CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700597-B2 | Substituted piperazines as CB1 antagonists | SCHERING CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| US-20100029607-A1 | Substituted Piperazines as CB1 Antagonists | SCHERING CORPORATION | 2010-02-04 | — | — | US | disclosed |
| US-20100029607-A1 | Substituted Piperazines as CB1 Antagonists | SCHERING CORPORATION | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029607-A1 | Substituted Piperazines as CB1 Antagonists | CNR1, CNR2, GPR119 | CNR1 1/4885MDM2 4116/4885OPRL1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.